| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Oropouche Virus Antibody (IgM)
Test Code16766
Preferred Specimen
1 mL Serum.
Collection Instructions:
__** This test is not available for New York patient
__testing. **
__
Collection Instructions:
__** This test is not available for New York patient
__testing. **
__
Minimum Volume
0.5 mL Serum
Transport Container
Serum
__Red-top (no gel) (preferred)
__SST (red-top)
__Red-top (no gel) (preferred)
__SST (red-top)
Transport Temperature
Serum: Room temperature preferred; Refrigerated acceptable;
_Frozen acceptable
_Frozen acceptable
Specimen Stability
Serum
__Room temperature: 7 Days
__Refrigerated: 14 Days
__Frozen: 30 Days
__Room temperature: 7 Days
__Refrigerated: 14 Days
__Frozen: 30 Days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Yes • Yes • Icteric
Methodology
Immunoassay
Setup Schedule
Sets up 1 day a week.
Report Available
Reports in 1 to 7 days.
Clinical Significance
This immunoassay is intended for the qualitative detection
of IgM antibodies to Oropouche virus in serum from patients
suspected of having acute infection. A positive IgM result
can help support diagnosis in a patient with the
appropriate risk factors presenting with signs and symptoms
consistent with Oropouche virus disease (Oropouche fever).
If additional testing is needed, please contact the public
health department.
Oropouche virus disease is a vector-borne infectious
disease that is primarily transmitted through the bite of
an infected midge or mosquito. The disease is primarily
found in South America and the Caribbean. Increasing cases
have been observed, including in US travelers, due to
several outbreaks occurring outside known endemic areas.
Symptomatic individuals typically present with fever,
severe headache, chills, muscle aches, and joint pain with
relapsing symptoms. These symptoms may overlap with other
vector-borne illnesses in the same geographic regions, such
as dengue, chikungunya, zika, or malaria. Complications
related to neuroinvasive disease, Guillain-Barre syndrome,
and vertical transmission in pregnant women have been
reported.
Although there is no specific treatment for Oropouche virus
disease, diagnostic testing is recommended to inform
clinical management. Viremia is highest during the first 7
days post symptom onset, therefore direct detection of
viral RNA using a molecular assay should be performed
during this timeframe. Antibodies are typically detected
starting 1 week post symptom onset. False negatives can
occur early during infection before seroconversion;
therefore, paired acute (within 2 weeks of illness) and
convalescent sera can be tested.
Reference:
1. Wesselmann K, et al. Lancet infectious Diseases. 2024;24
:e439-452
2. Updated Interim Guidance for Health Departments on
Testing and Reporting for Oropouche Virus Disease.
https://www.cdc.gov/oropouche/php/reporting/index.html
Last updated April 10, 2025.
of IgM antibodies to Oropouche virus in serum from patients
suspected of having acute infection. A positive IgM result
can help support diagnosis in a patient with the
appropriate risk factors presenting with signs and symptoms
consistent with Oropouche virus disease (Oropouche fever).
If additional testing is needed, please contact the public
health department.
Oropouche virus disease is a vector-borne infectious
disease that is primarily transmitted through the bite of
an infected midge or mosquito. The disease is primarily
found in South America and the Caribbean. Increasing cases
have been observed, including in US travelers, due to
several outbreaks occurring outside known endemic areas.
Symptomatic individuals typically present with fever,
severe headache, chills, muscle aches, and joint pain with
relapsing symptoms. These symptoms may overlap with other
vector-borne illnesses in the same geographic regions, such
as dengue, chikungunya, zika, or malaria. Complications
related to neuroinvasive disease, Guillain-Barre syndrome,
and vertical transmission in pregnant women have been
reported.
Although there is no specific treatment for Oropouche virus
disease, diagnostic testing is recommended to inform
clinical management. Viremia is highest during the first 7
days post symptom onset, therefore direct detection of
viral RNA using a molecular assay should be performed
during this timeframe. Antibodies are typically detected
starting 1 week post symptom onset. False negatives can
occur early during infection before seroconversion;
therefore, paired acute (within 2 weeks of illness) and
convalescent sera can be tested.
Reference:
1. Wesselmann K, et al. Lancet infectious Diseases. 2024;24
:e439-452
2. Updated Interim Guidance for Health Departments on
Testing and Reporting for Oropouche Virus Disease.
https://www.cdc.gov/oropouche/php/reporting/index.html
Last updated April 10, 2025.
